A Pilot, 8-Week, Placebo Lead-In Trial of Quetiapine Extended Release for Depression in Midlife Women: Impact on Mood and Menopause-Related Symptoms

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 612-615

  Soares, Claudio N ^a,b   Frey, Benicio N ^a,b   Haber, Erika ^b   Steiner, Meir ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Women's Health Concerns Clinic   (Canada)

Author keywords

depression; hot flashes; menopause; perimenopause; quetiapine; vasomotor symptoms

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; ARTICLE; BLOATING; BODY WEIGHT; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DREAMING; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HOT FLUSH; HUMAN; MENOPAUSE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; PARESTHESIA; PATIENT COMPLIANCE; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUSTAINED RELEASE FORMULATION; SYMPTOM; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AFFECT; AGE FACTORS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PILOT PROJECTS; SINGLE-BLIND METHOD;

EID: 77957281840     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f1d0f2     Document Type: Article

References (21)

1. Nelson HD. Menopause. Lancet. 2008;371: 760-770.
2. Santoro N, Brown JR, Adel T, et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81: 1495-1501. (Pubitemid 26118582)
3. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women s Health Across the Nation (SWAN). J Affect Disord. 2007;103(1-3): 267-272.
4. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63: 385-390.
5. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63: 375-382.
6. Woods NF, Smith-DiJulio K, Percival DB, et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women s Health Study. Menopause. 2008;15: 223-232.
7. Stahl SM. Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry. 2009;70: 11-12.
8. Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause Int. 2008;14: 123-128.
9. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183: 414-420. (Pubitemid 30651090)
10. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58: 529-534. (Pubitemid 32523731)
11. Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55: 406-412. (Pubitemid 38199991)
12. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri-and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006;13: 780-786. (Pubitemid 44435032)
13. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68: 943-950. (Pubitemid 47015497)
14. Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009;200: 238.e1-238.e10.
15. Soules M, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76: 874-878. (Pubitemid 33031310)
16. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry. 1998;59(suppl 20): 22-33; quiz 4-57. (Pubitemid 29001829)
17. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29: 25-31.
18. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. 2001;22: 979-989.
19. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine s antidepressant activity. Neuropsychopharmacology. 2008;33(10): 2303-2312.
20. Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Poster presented at the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC. Poster NR5-126.
21. Freedman RR, Roehrs TA. Lack of sleep disturbance from menopausal hot flashes. Fertil Steril. 2004;82: 138-144. (Pubitemid 38968789)